Comparing RegeneRx Biopharmaceuticals (OTCMKTS:RGRX) and Johnson & Johnson (NYSE:JNJ)

RegeneRx Biopharmaceuticals (OTCMKTS:RGRX) and Johnson & Johnson (NYSE:JNJ) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, dividends, profitability, analyst recommendations, valuation, risk and institutional ownership.

Analyst Recommendations

This is a summary of recent recommendations and price targets for RegeneRx Biopharmaceuticals and Johnson & Johnson, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
RegeneRx Biopharmaceuticals	0	0	0	0	0.00
Johnson & Johnson	0	7	6	0	2.46

Johnson & Johnson has a consensus price target of $174.71, indicating a potential upside of 22.37%. Given Johnson & Johnson’s stronger consensus rating and higher possible upside, analysts clearly believe Johnson & Johnson is more favorable than RegeneRx Biopharmaceuticals.

Institutional & Insider Ownership

69.6% of Johnson & Johnson shares are held by institutional investors. 12.6% of RegeneRx Biopharmaceuticals shares are held by insiders. Comparatively, 0.2% of Johnson & Johnson shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Valuation & Earnings

This table compares RegeneRx Biopharmaceuticals and Johnson & Johnson”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
RegeneRx Biopharmaceuticals	$80,000.00	0.03	-$1.73 million	N/A	N/A
Johnson & Johnson	$87.70 billion	3.92	$35.15 billion	$6.91	20.66

Johnson & Johnson has higher revenue and earnings than RegeneRx Biopharmaceuticals.

Volatility and Risk

RegeneRx Biopharmaceuticals has a beta of 2.75, suggesting that its stock price is 175% more volatile than the S&P 500. Comparatively, Johnson & Johnson has a beta of 0.51, suggesting that its stock price is 49% less volatile than the S&P 500.

Profitability

This table compares RegeneRx Biopharmaceuticals and Johnson & Johnson’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
RegeneRx Biopharmaceuticals	N/A	N/A	N/A
Johnson & Johnson	19.14%	35.45%	14.23%

Summary

Johnson & Johnson beats RegeneRx Biopharmaceuticals on 10 of the 12 factors compared between the two stocks.

About RegeneRx Biopharmaceuticals

RegeneRx Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of therapeutic peptide, Thymosin beta 4, for tissue and organ protection, repair, and regeneration. The company is developing RGN-259, a preservative-free topical eye drop for regeneration of corneal tissues damaged by injury, disease, or other pathology; RGN-352, an injectable formulation for the treatment of cardiovascular diseases, central and peripheral nervous system diseases, and other medical indications; and RGN-137, a topical gel for the treatment of dermal wounds and reduction of scar tissue. It has strategic partnerships with Lee's Pharmaceutical Group and HLB Therapeutics. The company was formerly known as Alpha 1 Biomedicals, Inc. and changed its name to RegeneRx Biopharmaceuticals, Inc. in 2000. RegeneRx Biopharmaceuticals, Inc. was incorporated in 1982 and is based in Rockville, Maryland.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. Its MedTech segment provides Interventional Solutions, including electrophysiology products to treat heart rhythm disorders; the heart recovery portfolio, which includes technologies to treat severe coronary artery disease requiring high-risk PCI or AMI cardiogenic shock; and neurovascular care that treats hemorrhagic and ischemic stroke. this segment also offers an orthopaedics portfolio that includes products and enabling technologies that support hips, knees, trauma, spine, sports, and other; surgery portfolios comprising advanced and general surgery technologies, as well as solutions for breast aesthetics, ear, nose, and throat procedures; contact lenses under the ACUVUE Brand; and TECNIS intraocular lenses for cataract surgery. It distributes its products to wholesalers, hospitals, and retailers, as well as physicians, nurses, hospitals, eye care professionals, and clinics. Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey.